In the ultracompetitive world of drug development, getting a new medication on the market as fast as possible can have major business implications. There’s perhaps no better recent example than Novo Nordisk, which has generated nearly $100 billion in sales of weight loss drugs Ozempic and Wegovy while trying to fend off competition from Eli Lilly.
Now, Novo Nordisk says it’s using AI agents to shorten by weeks or months the time it takes to both start new clinical trials and to complete them. The new tools are expected to add tens or hundreds of millions of dollars in additional revenue while helping the company hire fewer employees, according to Chief Digital Officer Stephanie Bova.
